×
AI could speed up FDA drug evaluation process
Written by
Published on
Join our daily newsletter for breaking news, product launches and deals, research breakdowns, and other industry-leading AI coverage
Join Now

The FDA is exploring a partnership with OpenAI to accelerate the drug approval process through artificial intelligence, potentially transforming how new medications reach patients. This initiative represents a significant shift in regulatory technology application, as the FDA commissioner recently revealed the agency has already completed its first AI-assisted scientific review and is actively pursuing further AI integration to address the decade-long timeline typically required for new drugs to reach the market.

The big picture: FDA commissioner Marty Makary has publicly questioned the lengthy drug approval process and signaled the agency’s commitment to modernization through artificial intelligence.

  • Makary wrote on social media: “Why does it take over 10 years for a new drug to come to market? Why are we not modernized with AI and other things? We’ve just completed our first AI-assisted scientific review for a product and that’s just the beginning.”
  • The commissioner discussed AI’s potential to accelerate approvals for diabetes treatments and certain cancer therapies during an American Hospital Association meeting.

Behind the scenes: OpenAI representatives have held multiple meetings with FDA officials and associates from Elon Musk‘s Department of Government Efficiency.

  • The discussions center around a project tentatively called cderGPT, likely referencing the FDA’s Center for Drug Evaluation and Research.
  • Jeremy Walsh, recently appointed as the FDA’s first AI officer, is leading these discussions with OpenAI.

Where things stand: Despite ongoing meetings between OpenAI and the FDA, no formal contract has been signed yet.

  • OpenAI has declined to comment on the potential partnership or the nature of the discussions.
  • The initiative appears to be in early exploratory stages, with multiple stakeholders involved in shaping the potential collaboration.

Why this matters: Implementing AI in the drug approval process could significantly reduce the time required to bring life-saving medications to market, potentially benefiting millions of patients waiting for new treatments.

OpenAI and the FDA Are Holding Talks About Using AI In Drug Evaluation

Recent News

AI courses from Google, Microsoft and more boost skills and résumés for free

As AI becomes critical to business decision-making, professionals can enhance their marketability with free courses teaching essential concepts and applications without requiring technical backgrounds.

Veo 3 brings audio to AI video and tackles the Will Smith Test

Google's latest AI video generation model introduces synchronized audio capabilities, though still struggles with realistic eating sounds when depicting the celebrity in its now-standard benchmark test.

How subtle biases derail LLM evaluations

Study finds language models exhibit pervasive positional preferences and prompt sensitivity when making judgments, raising concerns for their reliability in high-stakes decision-making contexts.